Nordic Nanovector ASA is angling to partner out the radioimmunoconjugate candidate Betalutin (177Lu lilotomab satetraxetan) as it plans to restructure following a negative interim analysis that led to the discontinuation of the Phase IIb PARADIGME trial of the drug in third-line follicular lymphoma (FL). The program had already faced recruitment challenges, and the company plans to focus its efforts on other assets in its pipeline as it seeks to reduce costs.
The Norway-based biotech said 5 July that it had chosen to discontinue PARADIGME following a comprehensive review and independent data evaluation, as well as a request for regulatory agency interaction